PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10678995
Filing Date	2003-10-03
First Named Inventor	Khan et al.
Art Unit	1651
Examiner Name	T. Underdahl
Attorney Docket Number	2183.03-4618.1US

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4330466		1982-05-18	Yanaihara et al.	
	2	5966712		1999-10-12	Sabatini et al.	
	3	6278794		2001-08-21	Parekh et al.	
	4	6379970		2002-04-30	Liebler et al.	
	5	6416959		2002-07-09	Giuliano et al.	
	6	6507788		2003-01-14	Camara y Ferrer et al.	
	7	6539102		2003-03-25	Anderson et al.	
	8	6711563		2004-03-23	Koskas	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TU/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678995
	Filing Date	2003-10-03
	First Named Inventor	Khan et al.
	Art Unit	1651
	Examiner Name	T. Underdahl
	Attorney Docket Number	2183.03-4618.1US

	9	6921751		2005-07-26	Khan et al.	
	10	7175679		2007-02-13	Khan et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020147306	A1	2002-10-10	Lin et al.	
	2	20050107314	A1	2005-05-19	Gorczynski et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] ¡	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2194886	GB	A	1988-03-23	The Wellcome Foundation Limited		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	AGAWAL et al., Acute Renal Failure, American Family Physician, 2000, pp. 2077-88, Vol. 61, corresponding to web version of p. 1-12.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TU/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678995
	Filing Date	2003-10-03
	First Named Inventor	Khan et al.
	Art Unit	1651
	Examiner Name	T. Underdahl
	Attorney Docket Number	2183.03-4618.1US

	2	BRADHAM et al., Activation of nuclear factor- κB during orthotopic liver transplantation in rats is protective and does not require Kuppfer cells, Liver Transplantation and Surgery, July 1999, pp. 282-93, Vol. 5, No. 4.	☐
	3	CLERICI et al., Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. Journal of Neuroimmunology, Vol. 121, pp. 33-101, 2001.	☐
	4	DE SAIZIEU et al., Journal of Bacteriology, Vol. 182, No. 17, pp. 4696-4703, September 2000.	☐
	5	DECHEND et al., Oncogene, Vol. 18, pp. 3316-3323, 1999.	☐
	6	GenBank Accession No. NP_000728, GI: 4502789, publicly available April 2007.	☐
	7	HAN et al., Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation, American Journal of Physiology, July 1999, Vol. 277, pp. C74-C82.	☐
	8	ICHIYAMA et al., Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation, Brain Research, July 1999, pp. 31-37, Vol. 836.	☐
	9	Keeton and Gould, Biological Science, 5th Ed., New York, W.W. Norton & Company, Inc. 1993, p. 4.	☐
	10	LIN et al., The Journal of Biological Chemistry, Vol. 270, No. 24, pp. 14255-58, June 1995.	☐
	11	MedlinePlus, Medical Encyclopedia: autoimmune disorders (www.nlm.gov/medlineplus/ency/article/000816.htm)	☐
	12	PCT International Search Report, PCT/EP2005/003707, dated July 5, 2005.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TU/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678995
	Filing Date	2003-10-03
	First Named Inventor	Khan et al.
	Art Unit	1651
	Examiner Name	T. Underdahl
	Attorney Docket Number	2183.03-4618.1US

	13	SHARMA, Septic Shock, (visited 9/27/2007 <http://www.emedicine.com/MED/topic2101.htm>.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature	/Thane Underdahl/	Date Considered	02/07/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TU/

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TU/